Sample list of current or past clients:
GlycoMimetics, Inc. – GlycoMimetics is an oncology-focused biotechnology company dedicated to improving the lives of patients living with orphan diseases by discovering, developing and commercializing novel, small-molecule glycomimetic product candidates. The management team consists of industry leaders with deep experience in the pharmaceutical/biotech industry. Since its inception, GlycoMimetics has developed a diversified product pipeline with two proprietary programs now in late-stage clinical development. Learn more at www.glycomimetics.com.
MaxCyte – MaxCyte is a global cell-based medicines and life sciences company applying its proprietary cell engineering technology platform to deliver the advances of cell-based medicine to patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte’s mRNA-based proprietary therapeutic platform for rapid autologous cell therapy for the treatment of solid cancers. In addition, through its core business, MaxCyte leverages its Flow Electroporation® Technology to enable its biopharmaceutical industry partners to advance the development of innovative, cutting-edge medicines, particularly in cell therapy, including the use of gene editing tools in the treatment of inherited genetic diseases and immuno-oncology approaches to treating cancer. MaxCyte has placed its cutting-edge flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies, has more than 70 partnered program licenses in cell therapy including more than 35 licensed for clinical use. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com.
UM Ventures – a joint initiative of the MPowering the State Program, bringing the University of Maryland, Baltimore and University of Maryland, College Park together to commercialize discoveries, and create economic impact by engaging partners in industry and social ventures. By encouraging our students and faculty, providing expert advice and business services, more discoveries will reach the market. By engaging directly with external partners we will bring new investment, expanded markets and more startup ventures. The UM Ventures internal Advisory Board was formed in August 2012. Its members are the Deans of Business, Engineering, and Computer, Mathematical and Natural Sciences at UMCP and the Deans of Law, Medicine, and Pharmacy at UMB. The Board is co-chaired by the UMCP Vice President of Research, and UMB Vice President of Enterprise and Economic Development. Learn more at http://www.umventures.org/.